Effects of Resveratrol Supplementation on Methotrexate Chemotherapy-Induced Bone Loss

Overview

Journal Nutrients

Date 2017 Mar 12

PMID 28282956

Citations 4

Authors

Alice M C Lee

Tetyana Shandala

Pei Pei Soo

Yu-Wen Su

Tristan J King

Ke-Ming Chen

Peter R Howe

Cory J Xian

Affiliations

Soon will be listed here.

Abstract

Intensive cancer chemotherapy is known to cause bone defects, which currently lack treatments. This study investigated the effects of polyphenol resveratrol (RES) in preventing bone defects in rats caused by methotrexate (MTX), a commonly used antimetabolite in childhood oncology. Young rats received five daily MTX injections at 0.75 mg/kg/day. RES was orally gavaged daily for seven days prior to, and during, five-day MTX administration. MTX reduced growth plate thickness, primary spongiosa height, trabecular bone volume, increased marrow adipocyte density, and increased mRNA expression of the osteogenic, adipogenic, and osteoclastogenic factors in the tibial bone. RES at 10 mg/kg was found not to affect bone health in normal rats, but to aggravate the bone damage in MTX-treated rats. However, RES supplementation at 1 mg/kg preserved the growth plate, primary spongiosa, bone volume, and lowered the adipocyte density. It maintained expression of genes involved in osteogenesis and decreased expression of adipogenic and osteoclastogenic factors. RES suppressed osteoclast formation ex vivo of bone marrow cells from the treated rats. These data suggest that MTX can enhance osteoclast and adipocyte formation and cause bone loss, and that RES supplementation at 1 mg/kg may potentially prevent these bone defects.

Citing Articles

Revisiting Resveratrol as an Osteoprotective Agent: Molecular Evidence from In Vivo and In Vitro Studies.

Hairi H, Jayusman P, Shuid A Biomedicines. 2023; 11(5).

PMID: 37239124 PMC: 10216404. DOI: 10.3390/biomedicines11051453.

Notch2 Blockade Mitigates Methotrexate Chemotherapy-Induced Bone Loss and Marrow Adiposity.

Peymanfar Y, Su Y, Xian C Cells. 2022; 11(9).

PMID: 35563828 PMC: 9103078. DOI: 10.3390/cells11091521.

Musculoskeletal Manifestations in Sjogren's Syndrome: An Orthopedic Point of View.

Rozis M, Vlamis J, Vasiliadis E, Mavragani C, Pneumaticos S, Evangelopoulos D J Clin Med. 2021; 10(8).

PMID: 33917955 PMC: 8068384. DOI: 10.3390/jcm10081574.

Short-term use of resveratrol in alloplastic graft material applied with calvarial bone defects in rats.

Lacin N, Deveci E Acta Cir Bras. 2019; 34(7):e201900704.

PMID: 31531539 PMC: 6746564. DOI: 10.1590/s0102-865020190070000004.

References

Ahmet I, Tae H, Lakatta E, Talan M . Long-term low dose dietary resveratrol supplement reduces cardiovascular structural and functional deterioration in chronic heart failure in rats. Can J Physiol Pharmacol. 2017; 95(3):268-274. PMC: 10542918. DOI: 10.1139/cjpp-2016-0512. View

Fan C, Foster B, Hui S, Xian C . Prevention of bone growth defects, increased bone resorption and marrow adiposity with folinic acid in rats receiving long-term methotrexate. PLoS One. 2012; 7(10):e46915. PMC: 3465278. DOI: 10.1371/journal.pone.0046915. View

Baile C, Yang J, Rayalam S, Hartzell D, Lai C, Andersen C . Effect of resveratrol on fat mobilization. Ann N Y Acad Sci. 2011; 1215:40-7. DOI: 10.1111/j.1749-6632.2010.05845.x. View

Habold C, Momken I, Ouadi A, Bekaert V, Brasse D . Effect of prior treatment with resveratrol on density and structure of rat long bones under tail-suspension. J Bone Miner Metab. 2010; 29(1):15-22. DOI: 10.1007/s00774-010-0187-y. View

Backesjo C, Li Y, Lindgren U, Haldosen L . Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J Bone Miner Res. 2006; 21(7):993-1002. DOI: 10.1359/jbmr.060415. View

King T, Georgiou K, Cool J, Scherer M, Ang E, Foster B . Methotrexate chemotherapy promotes osteoclast formation in the long bone of rats via increased pro-inflammatory cytokines and enhanced NF-κB activation. Am J Pathol. 2012; 181(1):121-9. DOI: 10.1016/j.ajpath.2012.03.037. View

Fischer-Posovszky P, Kukulus V, Tews D, Unterkircher T, Debatin K, Fulda S . Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. Am J Clin Nutr. 2010; 92(1):5-15. DOI: 10.3945/ajcn.2009.28435. View

Fan C, Georgiou K, McKinnon R, Keefe D, Howe P, Xian C . Combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil causes trabecular bone loss, bone marrow cell depletion and marrow adiposity in female rats. J Bone Miner Metab. 2015; 34(3):277-90. DOI: 10.1007/s00774-015-0679-x. View

Shandala T, Shen Ng Y, Hopwood B, Yip Y, Foster B, Xian C . The role of osteocyte apoptosis in cancer chemotherapy-induced bone loss. J Cell Physiol. 2011; 227(7):2889-97. DOI: 10.1002/jcp.23034. View

10.

Georgiou K, King T, Scherer M, Zhou H, Foster B, Xian C . Attenuated Wnt/β-catenin signalling mediates methotrexate chemotherapy-induced bone loss and marrow adiposity in rats. Bone. 2012; 50(6):1223-33. DOI: 10.1016/j.bone.2012.03.027. View

11.

Mondal A, Bennett L . Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARP cleavage. Biomed Pharmacother. 2016; 84:1906-1914. DOI: 10.1016/j.biopha.2016.10.096. View

12.

Georgiou K, Nadhanan R, Fan C, Xian C . Methotrexate-induced bone marrow adiposity is mitigated by folinic acid supplementation through the regulation of Wnt/β-catenin signalling. J Cell Physiol. 2014; 230(3):648-56. DOI: 10.1002/jcp.24788. View

13.

Gass M, Dawson-Hughes B . Preventing osteoporosis-related fractures: an overview. Am J Med. 2006; 119(4 Suppl 1):S3-S11. DOI: 10.1016/j.amjmed.2005.12.017. View

14.

Georgiou K, Foster B, Xian C . Damage and recovery of the bone marrow microenvironment induced by cancer chemotherapy - potential regulatory role of chemokine CXCL12/receptor CXCR4 signalling. Curr Mol Med. 2010; 10(5):440-53. DOI: 10.2174/156652410791608243. View

15.

Chen Y, Lien H, Kao M, Lo U, Lin L, Lin C . Sensitization of Radioresistant Prostate Cancer Cells by Resveratrol Isolated from Arachis hypogaea Stems. PLoS One. 2017; 12(1):e0169204. PMC: 5231355. DOI: 10.1371/journal.pone.0169204. View

16.

Lee A, Shandala T, Nguyen L, Muhlhausler B, Chen K, Howe P . Effects of resveratrol supplementation on bone growth in young rats and microarchitecture and remodeling in ageing rats. Nutrients. 2014; 6(12):5871-87. PMC: 4277004. DOI: 10.3390/nu6125871. View

17.

Tseng P, Hou S, Chen R, Peng H, Hsieh C, Kuo M . Resveratrol promotes osteogenesis of human mesenchymal stem cells by upregulating RUNX2 gene expression via the SIRT1/FOXO3A axis. J Bone Miner Res. 2011; 26(10):2552-63. DOI: 10.1002/jbmr.460. View

18.

He X, Andersson G, Lindgren U, Li Y . Resveratrol prevents RANKL-induced osteoclast differentiation of murine osteoclast progenitor RAW 264.7 cells through inhibition of ROS production. Biochem Biophys Res Commun. 2010; 401(3):356-62. DOI: 10.1016/j.bbrc.2010.09.053. View

19.

Yang Y, Li C, Li H, Wu M, Ren C, Zhen Y . Differential sensitivities of bladder cancer cell lines to resveratol are unrelated to its metabolic profile. Oncotarget. 2017; 8(25):40289-40304. PMC: 5522211. DOI: 10.18632/oncotarget.15041. View

20.

Georgiou K, Hui S, Xian C . Regulatory pathways associated with bone loss and bone marrow adiposity caused by aging, chemotherapy, glucocorticoid therapy and radiotherapy. Am J Stem Cells. 2013; 1(3):205-24. PMC: 3636730. View